{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:04:53Z","timestamp":1780488293735,"version":"3.54.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Peripheral T-cell lymphoma (PTCL) is a rare form of lymphoma in children with limited published data on treatment and lack of a uniformly accepted treatment algorithm. We retrospectively analyzed the data in children up to 18 years of age diagnosed to have PTCL from January 2016 to June 2020. The study included six children with a median age of 10 years, the youngest being a 7-month-old girl. According to the WHO-PTCL classification, three had PTCL-not otherwise specified (NOS), 2 had hepatosplenic TCL, and 1 had subcutaneous panniculitis-like TCL. All children had presented with advanced disease, 4 in St. Jude stage IV, 2 in St. Jude stage III. Three children received CHOEP chemotherapy including cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, while 1 child received CHOP. Two children received induction as per acute lymphoblastic leukemia followed by Bendamustine. Two patients succumbed to progressive disease, the infant with PTCL-NOS and 1 child with hepatosplenic TCL. Three children were in remission (median follow up of 44\u2009mo). One child with PTCL-NOS Stage IV had an underlying STAT3 mutated hyperimmunoglobulin E syndrome and was in remission 12 months post a matched unrelated donor hematopoietic stem cell transplantation. He had grade 4 skin graft versus host disease and required extracorporeal photopheresis and ibrutinib, to which he had responded. CHOEP chemotherapy is well-tolerated and subcutaneous panniculitis-like TCL has the best prognosis thus far.<\/jats:p>","DOI":"10.1097\/mph.0000000000002364","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T22:02:18Z","timestamp":1638568938000},"page":"e849-e854","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Management of Peripheral T-Cell Lymphoma in Children and Adolescents Including STAT 3 Mutation Hyper-IgE Syndrome: One Size Does Not Fit All"],"prefix":"10.1097","volume":"44","author":[{"given":"Nikila","family":"Ravichandran","sequence":"first","affiliation":[{"name":"Pediatric Hematology, Oncology, Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Uppuluri","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, Oncology, Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateswaran","family":"Vellaichamy Swaminathan","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, Oncology, Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesavan","family":"Melarcode Ramanan","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, Oncology, Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satishkumar","family":"Meena","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, Oncology, Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harika","family":"Varla","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, Oncology, Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumesh","family":"Chandar","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, Oncology, Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Jayakumar","sequence":"additional","affiliation":[{"name":"Pediatric Critical Care, Apollo Hospitals, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revathi","family":"Raj","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, Oncology, Blood and Marrow Transplantation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.1995.13.2.359","article-title":"Non-Hodgkin\u2019s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage\u2014a report of the Berlin-Frankfurt-M\u00fcnster Group","volume":"13","author":"Reiter","year":"1995","journal-title":"J Clin Oncol"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/MPH.0b013e3182707592","article-title":"Peripheral T-cell lymphoma in children and adolescents\u202f: a single-institution experience","volume":"34","author":"Mahmoud","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00277-016-2722-y","article-title":"Non-anaplastic peripheral T cell lymphoma in children and adolescents\u2014an international review of 143 cases","volume":"95","author":"Mellgren","year":"2016","journal-title":"Ann Hematol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/pbc.25881","article-title":"Rare pediatric non-Hodgkin lymphomas: a report from Children\u2019s Oncology Group Study ANHL 04B1","volume":"63","author":"O\u2019Suoji","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"suppl 1","key":"R7-20250804","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hon.2846","article-title":"What\u2019s new in peripheral T-cell lymphomas","volume":"39","author":"Luminari","year":"2021","journal-title":"Hematol Oncol"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","article-title":"Revised international pediatric non-Hodgkin lymphoma staging system","volume":"33","author":"Rosolen","year":"2015","journal-title":"J Clin Oncol"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/annonc\/mdh409","article-title":"Towards understanding the peripheral T-cell lymphomas","volume":"15","author":"Armitage","year":"2004","journal-title":"Ann Oncol"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/pbc.21543","article-title":"Non-anaplastic peripheral T-cell lymphoma in childhood and adolescence: a Children\u2019s Oncology Group study","volume":"51","author":"Hutchison","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/pbc.21293","article-title":"Peripheral T-cell lymphoma in childhood\u202f: population-based experience in the United Kingdom over 20 years","volume":"50","author":"Windsor","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bjh.13216","article-title":"Non-anaplastic peripheral T-cell lymphoma in children and adolescents\u2014a retrospective analysis of the NHL-BFM study group","volume":"168","author":"Kontny","year":"2015","journal-title":"Br J Haematol"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2002-04-1200","article-title":"G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases","volume":"102","author":"Franzke","year":"2003","journal-title":"Blood"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V95.7.2269","article-title":"Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo","volume":"95","author":"Sloand","year":"2000","journal-title":"Blood"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/hematology.2020000101","article-title":"Strategies for aggressive T-cell lymphoma: divide and conquer","volume":"2020","author":"Pinter-Brown","year":"2020","journal-title":"Hematology"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1346-8138.2002.tb00271.x","article-title":"A case of hyper-IgE syndrome complicated by cutaneous, nodal, and liver peripheral T cell lymphomas","volume":"29","author":"Chang","year":"2002","journal-title":"J Dermatol"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/pbc.25565","article-title":"Non-Hodgkin lymphoma in children with an associated inherited condition: a retrospective analysis of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)","volume":"62","author":"Aric\u00f2","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/PPO.0b013e31826aeeb2","article-title":"Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: No\u2026 Well Yes, \u2026But Maybe Not for Long","volume":"18","author":"Moskowitz","year":"2012","journal-title":"Cancer J"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00277-013-1746-9","article-title":"Bendamustine salvage therapy for T cell neoplasms","volume":"92","author":"Zaja","year":"2013","journal-title":"Ann Hematol"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"85573","DOI":"10.18632\/oncotarget.10764","article-title":"Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: a French retrospective multicenter study","volume":"7","author":"Reboursiere","year":"2016","journal-title":"Oncotarget"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.3892\/ol.2016.4213","article-title":"Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: a case report and review of the literature","volume":"11","author":"Du","year":"2016","journal-title":"Oncol Lett"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.3109\/10428194.2013.780289","article-title":"Bortezomib salvage therapy in refractory acute adult T-cell leukemia\/lymphoma","volume":"54","author":"Hourigan","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"key":"R31-20250804","first-page":"4649","article-title":"Celecoxib enhances sensitivity to chemotherapy drugs of T-cell lymphoma","volume":"15","author":"Ma","year":"2018","journal-title":"Oncol Lett"},{"key":"R32-20250804","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.advms.2016.03.002","article-title":"Clinical features and treatment outcomes of peripheral T-cell lymphoma in children. A current data report from Polish Pediatric Leukemia\/Lymphoma Study Group (PPLLSG)","volume":"61","author":"Maciejka-Kemblowska","year":"2016","journal-title":"Adv Med Sci"},{"key":"R33-20250804","doi-asserted-by":"crossref","first-page":"58396","DOI":"10.18632\/oncotarget.11135","article-title":"The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)\/T-cell lymphoma, nasal type","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"R34-20250804","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.16428","article-title":"The new biology of PTCL-NOS and AITL: current status and future clinical impact","volume":"189","author":"Timmins","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:03:28Z","timestamp":1754337808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002364","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,3]]},"assertion":[{"value":"2021-03-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}